AU Patent

AU2021201259A1 — Sublingual apomorphine

Assigned to Sumitomo Pharma America Inc · Expires 2021-03-18 · 5y expired

What this patent protects

The invention features sublingual formulations of apomorphine and apomorphine prodrugs, and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith.

USPTO Abstract

The invention features sublingual formulations of apomorphine and apomorphine prodrugs, and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith.

Drugs covered by this patent

apomorphine-hydrochloride (APOMORPHINE HYDROCHLORIDE)

Patent Metadata

Patent number: AU2021201259A1
Jurisdiction: AU
Classification: —
Expires: 2021-03-18
Drug substance claim: No
Drug product claim: No
Assignee: Sumitomo Pharma America Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.